Domainex Ltd.. (12/6/17). "Press Release: Domainex Appoints Chris Brown as Chief Financial Officer". Cambridge.

	Organisation	Domainex Ltd.
	Organisation 2	Envigo (Group)
	Product	drug discovery services
	Product 2	contract research (drugs)
	Person	Brown, Chris (Domainex 201712– CFO before Envigo)
	Person 2	Mander, Thomas (Tom) (Domainex 202004– CEO joined 201504 as COO before Charles River + Asterand + Tripos UK + Evotec)

Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Chris Brown has been appointed Chief Financial Officer with immediate effect.

Chris will have a pivotal role in supporting the organisation through ongoing and significant growth and investment; his appointment will strengthen both the existing Board and Executive Management Team. Domainex is expanding rapidly, with compounded annual growth in revenue of over 30% per annum during the past five years and an increase in its international team of scientists at the company’s research facilities on the Chesterford Research Park near Cambridge UK, by more than 50% in the past 12 months.

‘I am thrilled to join Domainex at this exciting stage of the company’s development,’ said Chris. ‘Domainex enjoys an outstanding reputation for scientific excellence in drug discovery. I believe we are in a strong position to build on our capabilities to serve our global client base. I look forward to developing and implementing our future growth strategies in drug discovery services.’

Chris Brown is a mathematics graduate of Imperial College and a Chartered Accountant. He has extensive experience within the life sciences industry with over 10 years at Envigo where he rose to become Senior Vice President of Finance. Chris Brown brings a strong financial technical skill set to the company and experience in M&A transactions having previously acted as the financial lead on the acquisition of Harlan Laboratories, a 2,000-person global scientific models and CRO business, to create Envigo.

‘We are delighted to welcome Chris to the team,’ commented Dr Timo Veromaa, Executive Chairman of the company. ‘We are exploring a number of exciting growth opportunities for Domainex, and feel Chris’ expertise will be of tremendous value in this area. I would also like to thank Barry Knight for his excellent service as our part-time CFO and wish him well in his future endeavours.’

For further information, contact:

Domainex

Dr Tom Mander
T: +44 (0) 7584 578 024
E: tom.mander@domainex.com

Media Relations – Sciad Communications

Deborah Cockerill / Emma Pick-up
T: +44 (0)20 7470 8801
E: domainex@sciad.com

About Domainex

Established in 2001 as a spin-out from University College London, Birkbeck College, and the Institute of Cancer Research, Domainex Ltd. is a Cambridge-based, privately-owned company that provides integrated medicines research services to global pharmaceutical, biotechnology and academic partners. Its services cover a wide span of the drug research value chain, from disease target selection to pre-clinical candidate nomination. Domainex's services include recombinant protein expression and use of its proprietary technology platform, Combinatorial Domain Hunting, to identify soluble protein fragments for structural biology and assay development. Hit finding activities encompass assay development and screening utilising its BioassayBuilder, FragmentBuilder and LeadBuilder platforms. The core of the service offering is undertaking multi-parameter medicinal chemistry optimisation of hits and leads with its ‘every compound counts’ approach, which can save up to 30% on the average industry time from target to candidate.

Record changed: 2023-06-05